Form 8-K - Current report:
SEC Accession No. 0001641172-25-009570
Filing Date
2025-05-12
Accepted
2025-05-12 08:05:14
Documents
15
Period of Report
2025-05-12
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 41940
2 EX-99.1 ex99-1.htm EX-99.1 75690
3 GRAPHIC ex99-1_001.jpg GRAPHIC 10465
  Complete submission text file 0001641172-25-009570.txt   318702

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE imnn-20250512.xsd EX-101.SCH 3009
5 XBRL LABEL FILE imnn-20250512_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE imnn-20250512_pre.xml EX-101.PRE 22355
17 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3688
Mailing Address 997 LENOX DRIVE SUITE 100 LAWRENCEVILLE NJ 08648
Business Address 997 LENOX DRIVE SUITE 100 LAWRENCEVILLE NJ 08648 (609) 896-9100
Imunon, Inc. (Filer) CIK: 0000749647 (see all company filings)

EIN.: 521256615 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-15911 | Film No.: 25932689
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)